Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features
暂无分享,去创建一个
Lindsay N. Carpp | Mathieu Le Gars | Ilse C. L. Van Dromme | Bethany L. Dearlove | Allan C. deCamp | Hongjun Bai | D. Follmann | O. Hyrien | P. Goepfert | Yanqing Sun | N. Garrett | K. Neuzil | L. Bekker | J. Sadoff | B. Williamson | A. Greninger | B. Grinsztejn | D. Benkeser | M. Juraska | M. Casapia | Pavitra Roychoudhury | J. Vingerhoets | M. Marovich | M. Losso | A. Gaur | C. Truyers | M. Rolland | S. Roels | A. Vandebosch | D. Stieh | C. Magaret | S. Little | L. Corey | Alex Luedtke | E. Swann | P. Gilbert | Cindy Molitor | Fei Heng | G. Gray | Leonardo Paiva de Sousa | Li Li | James Ludwig | Brian Simpkins
[1] D. Follmann,et al. A Covid-19 Milestone Attained - A Correlate of Protection for Vaccines. , 2022, The New England journal of medicine.
[2] Lindsay N. Carpp,et al. Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial , 2022, Nature Microbiology.
[3] W. Wu,et al. Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance , 2022, Nature medicine.
[4] D. Khoury,et al. Neutralising antibodies predict protection from severe COVID-19 , 2022, medRxiv.
[5] K. Subbarao,et al. Correlates of protection, thresholds of protection, and immunobridging in SARS-CoV-2 infection , 2022, medRxiv.
[6] H. Schuitemaker,et al. Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials , 2022, Vaccine.
[7] J. Bloom,et al. An antibody-escape estimator for mutations to the SARS-CoV-2 receptor-binding domain , 2022, Virus evolution.
[8] Catharine I Paules,et al. SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis , 2022, BMC Infectious Diseases.
[9] Marcelo A. Navarrete,et al. Differential neutralizing antibody responses elicited by CoronaVac and BNT162b2 against SARS-CoV-2 Lambda in Chile , 2022, Nature Microbiology.
[10] J. Bloom,et al. The SARS-CoV-2 Delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes , 2022, bioRxiv.
[11] H. Schuitemaker,et al. Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S , 2022, The New England journal of medicine.
[12] S. Zeger,et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression , 2022, The Lancet.
[13] Mark M. Davis,et al. Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses , 2022, Science Translational Medicine.
[14] J. Doudna,et al. Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles , 2021, medRxiv.
[15] Lindsay N. Carpp,et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial , 2021, Science.
[16] M. Davenport,et al. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis , 2021, The Lancet Microbe.
[17] J. Bloom,et al. A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy , 2021, bioRxiv.
[18] E. Kerwin,et al. Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial , 2021, medRxiv.
[19] T. Bedford,et al. SARS-CoV-2 Variants in Patients with Immunosuppression. , 2021, The New England journal of medicine.
[20] Z. Ning,et al. Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies , 2021, PLoS pathogens.
[21] F. Rey,et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization , 2021, Nature.
[22] J. Zahradník,et al. SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity , 2021, Cell Host & Microbe.
[23] H. Schuitemaker,et al. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans , 2021, Nature.
[24] William T. Harvey,et al. SARS-CoV-2 variants, spike mutations and immune escape , 2021, Nature Reviews Microbiology.
[25] M. Davenport,et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection , 2021, Nature Medicine.
[26] R. Andino,et al. Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant , 2021, Cell.
[27] P. Dormitzer,et al. Neutralizing Activity of BNT162b2-Elicited Serum , 2021, The New England journal of medicine.
[28] P. Gilbert,et al. Sieve analysis to understand how SARS-CoV-2 diversity can impact vaccine protection , 2021, PLoS pathogens.
[29] M. Beltramello,et al. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2 , 2021, bioRxiv.
[30] J. Bloom,et al. Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies , 2021, bioRxiv.
[31] S. Rowland-Jones,et al. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus , 2020, Cell.
[32] Jesse D. Bloom,et al. Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding , 2020, bioRxiv.
[33] Brian D. Williamson,et al. A General Framework for Inference on Algorithm-Agnostic Variable Importance , 2020, Journal of the American Statistical Association.
[34] Michal Juraska,et al. Mark-specific hazard ratio model with missing multivariate marks , 2016, Lifetime data analysis.
[35] Peter B Gilbert,et al. Covariability of selected amino acid positions for HIV type 1 subtypes C and B. , 2005, AIDS research and human retroviruses.
[36] C. Dolea,et al. World Health Organization , 1949, International Organization.
[37] S. Self,et al. Sieve analysis: methods for assessing from vaccine trial data how vaccine efficacy varies with genotypic and phenotypic pathogen variation. , 2001, Journal of clinical epidemiology.